Blar i Discussion papers (SAM) på forfatter "Holmås, Tor Helge"

Viser treff 1-8 av 8

    • Assessing the effects of early retirement programs 

      Bratberg, Espen; Holmås, Tor Helge; Thøgersen, Øystein (Discussion paper, Working paper, 2000-04)
      We investigate induced retirement effects of the Norwegian early retirement program ”AFP” and emphasize effects caused by relocations of some individuals from disability pension to AFP. Our theoretical model predicts ...

    • Competition and physician behaviour: Does the competitive environment affect the propensity to issue sickness certificates? 

      Brekke, Kurt R.; Holmås, Tor Helge; Monstad, Karin; Straume, Odd Rune (DP SAM;3, Working paper, 2017)
      Competition among physicians is widespread, but compelling empirical evidence on the impact on service provision is limited, mainly due to lack of exogenous variation in the degree of competition. In this paper we exploit ...

    • Diffusion of pharmaceuticals : cross-country evidence of anti-TNF drugs 

      Brekke, Kurt Richard; Dalen, Dag Morten; Holmås, Tor Helge (Discussion paper;7/2013, Working paper, 2013-03)
      This paper studies the diffusion of biopharmaceuticals across European countries, focusing on anti-TNF drugs, which are used to treat autoimmune diseases (e.g., rheumatism, psoriasis). We use detailed sales information on ...

    • Do Treatment Decisions Depend on Physicians` Financial Incentives? 

      Brekke, Kurt R.; Holmås, Tor Helge; Karin, Monstad; Straume, Odd Rune (Discussion paper;15/15, Working paper, 2015-07)
      We study whether and how physicians respond to financial incentives, making use of detailed register data on the health-care services provided to patients by general practitioners (GPs) in Norway over a six-year period ...

    • Margins and market shares : pharmacy incentives for generic substitution 

      Brekke, Kurt Richard; Straume, Odd Rune; Holmås, Tor Helge (Discussion paper, Working paper, 2010-07)
      We study the impact of product margins on pharmacies incentive to promote generics instead of brand-names. First, we construct a theoretical model where pharmacies can persuade patients with a brand-name prescription to ...

    • Regulation and pricing of pharmaceuticals : reference pricing or price cap regulation? 

      Grasdal, Astrid Louise; Brekke, Kurt Richard; Holmås, Tor Helge (Discussion paper, Working paper, 2006-09)
      We study the relationship between regulatory regimes and pharmaceutical firms’ pricing strategies using a unique policy experiment from Norway, which in 2003 introduced a reference price (RP) system called “index pricing” ...

    • Regulation, generic competition and pharmaceutical prices : theory and evidence from a natural experiment 

      Brekke, Kurt Richard; Holmås, Tor Helge; Straume, Odd Rune (Discussion paper, Working paper, 2007-12)
      We study the impact of regulatory regimes on generic competition and pharmaceutical pricing using a unique policy experiment in Norway, where reference pricing (RP) replaced price cap regulation in 2003 for a sub-sample ...

    • Socioeconomic Status and Physicians’ Treatment Decisions 

      Brekke, Kurt R.; Holmås, Tor Helge; Monstad, Karin; Straume, Odd Rune (Discussion paper;12/15, Working paper, 2015-06)
      This paper aims at shedding light on the social gradient by studying the relationship between socioeconomic status (SES) and provision of health care. Using administrative data on services provided by General Practitioners ...